Highlights of the 30th International Conference on Antiviral Research

. 2017 Sep ; 145 () : 184-196. [epub] 20170801

Jazyk angličtina Země Nizozemsko Médium print-electronic

Typ dokumentu kongresy

Perzistentní odkaz   https://www.medvik.cz/link/pmid28774800

The 30th International Conference on Antiviral Research (ICAR) was held in Atlanta, GA, USA from May 18 to 21, 2017. This report provides an account of award lectures, invited keynote addresses and oral presentations during the meeting. The 2017 Gertrude Elion Memorial Lecture Award by Michael Sofia highlighted one of the most important accomplishments in recent drug discovery in antiviral research, the identification of the hepatitis C virus direct-acting antiviral sofosbuvir and new alternatives to combat hepatitis B virus (HBV) infection. The Antonín Holý Lecture Award by David Chu on medicinal chemistry provided an overview of early developments of nucleoside analogs for the treatment of HIV and varicella zoster virus infection and how this knowledge serves to develop new drugs targeting HBV. Priscilla Yang gave the first ISAR Women in Science lecture. She reported on pharmacological validation of new antiviral targets for dengue, Zika and other flaviviruses. The William Prusoff Young Investigator Lecture Award by Maaike Everts described the Alabama Drug Discovery Alliance and the Antiviral Drug Discovery and Development Consortium, and how they are helping to accelerate the development of new antivirals. The 30th ICAR was a success in promoting new discoveries in antiviral drug development and research. The 31st ICAR will be held in Porto, Portugal, June 11-15, 2018.

Zobrazit více v PubMed

Bird B.H., Shrivastava-Ranjan P., Dodd K.A., Erickson B.R., Spiropoulou C.F. Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome. Antivir. Res. 2016;132:66–69. PubMed

Bonnelykke K., Sleiman P., Nielsen K., Kreiner-Moller E., Mercader J.M., Belgrave D., den Dekker H.T., Husby A., Sevelsted A., Faura-Tellez G., Mortensen L.J., Paternoster L., Flaaten R., Molgaard A., Smart D.E., Thomsen P.F., Rasmussen M.A., Bonas-Guarch S., Holst C., Nohr E.A., Yadav R., March M.E., Blicher T., Lackie P.M., Jaddoe V.W., Simpson A., Holloway J.W., Duijts L., Custovic A., Davies D.E., Torrents D., Gupta R., Hollegaard M.V., Hougaard D.M., Hakonarson H., Bisgaard H. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat. Genet. 2014;46:51–55. PubMed

Campos R.K., Wong B., Xie X., Lu Y.-F., Shi P.-Y., Pompon J., Garcia-Blanco M.A., Bradrick S.S. RPLP1 and RPLP2 are essential flavivirus host factors that promote early viral protein accumulation. J. Virol. 2017;91 PubMed PMC

Chen H., Boudinot F.D., Chu C.K., McClure H.M., Schinazi R.F. Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys. Antimicrob. Agents Chemother. 1996;40:2332–2336. PubMed PMC

Choi Y., Li L., Grill S., Gullen E., Lee C.S., Gumina G., Tsujii E., Cheng Y.C., Chu C.K. Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses. J. Med. Chem. 2000;43:2538–2546. PubMed

Chu C.K., Yadav V., Chong Y.H., Schinazi R.F. Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism. J. Med. Chem. 2005;48:3949–3952. PubMed

Chu J.J., Yang P.L. c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc. Natl. Acad. Sci. U. S. A. 2007;104:3520–3525. PubMed PMC

Clark M., Midituru C., Schmidt A., Zhu X., Pitts J., Wang J., Potisopon S., Zhang J., Wojciechowski A., Chu J.-H., Gray N., Yang P. GNF-2 inhibits dengue virus by targeting Abl kinases and the viral E protein. Cell Chem. Biol. 2005;23:443–452. PubMed PMC

Clark M.J., Miduturu C., Schmidt A.G., Zhu X., Pitts J.D., Wang J., Potisopon S., Zhang J., Wojciechowski A., Hann Chu J.J., Gray N.S., Yang P.L. GNF-2 inhibits dengue virus by targeting Abl kinases and the viral E protein. Cell Chem. Biol. 2016;23:443–452. PubMed PMC

De C., Liu D., Zheng B., Singh U.S., Chavre S., White C., Arnold R.D., Hagen F.K., Chu C.K., Moffat J.F. beta-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism. Antivir. Res. 2014;110:10–19. PubMed PMC

Everts M., Cihlar T., Bostwick J.R., Whitley R.J. Accelerating drug development: antiviral therapies for emerging viruses as a model. Annu. Rev. Pharmacol. Toxicol. 2017;57:155–169. PubMed

Everts M., Knight W.B., Harris D.R., Secrist J.A., 3rd, Whitley R.J. The Alabama Drug Discovery Alliance: a collaborative partnership to facilitate academic drug discovery. Pharm. Res. 2011;28:1454–1459. PubMed PMC

Everts M., Suto M.J., Painter G.R., Whitley R.J. Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective. Future Virol. 2016;11:187–195. PubMed PMC

Furman P.A., Jeffrey J., Kiefer L.L., Feng J.Y., Anderson K.S., Borroto-Esoda K., Hill E., Copeland W.C., Chu C.K., Sommadossi J.P., Liberman I., Schinazi R.F., Painter G.R. Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. Antimicrob. Agents Chemother. 2001;45:158–165. PubMed PMC

Gane E.J., Roberts S.K., Stedman C.A., Angus P.W., Ritchie B., Elston R., Ipe D., Morcos P.N., Baher L., Najera I., Chu T., Lopatin U., Berrey M.M., Bradford W., Laughlin M., Shulman N.S., Smith P.F. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–1475. PubMed

Haasbach E., Müller C., Ehrhardt C., Schreiber A., Pleschka S., Ludwig S., Planz O. The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo. Antivir. Res. 2017;142:178–184. PubMed

Le Pogam S., Seshaadri A., Ewing A., Kang H., Kosaka A., Yan J.M., Berrey M., Symonds B., De La Rosa A., Cammack N., Najera I. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J. Infect. Dis. 2010;202:1510–1519. PubMed

Li G.D., De Clercq E. Current therapy for chronic hepatitis C: the role of direct-acting antivirals. Antivir. Res. 2017;142:83–122. PubMed PMC

Lo M.K., Jordan R., Arvey A., Sudhamsu J., Shrivastava-Ranjan P., Hotard A.L., Flint M., McMullan L.K., Siegel D., Clarke M.O., Mackman R.L., Hui H.C., Perron M., Ray A.S., Cihlar T., Nichol S.T., Spiropoulou C.F. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 2017;7:43395. PubMed PMC

Ma T., Pai S.B., Zhu Y.L., Lin J.S., Shanmuganathan K., Du J., Wang C., Kim H., Newton M.G., Cheng Y.C., Chu C.K. Structure–activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. J. Med. Chem. 1996;39:2835–2843. PubMed

Modis Y., Ogata S., Clements D., Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 2003;100:6986–6991. PubMed PMC

Modis Y., Ogata S., Clements D., Harrison S.C. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427:313–319. PubMed

Mónaco D.C., Dilernia D.A., Fiore-Gartland A., Yu T., Prince J.L., Dennis K.K., Qin K., Schaefer M., Claiborne D.T., Kilembe W., Tang J., Price M.A., Farmer P., Gilmour J., Bansal A., Allen S., Goepfert P., Hunter E. Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression. J. Exp. Med. 2016;213:2049–2063. PubMed PMC

Peek S.F., Cote P.J., Jacob J.R., Toshkov I.A., Hornbuckle W.E., Baldwin B.H., Wells F.V., Chu C.K., Gerin J.L., Tennant B.C., Korba B.E. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax) Hepatology. 2001;33:254–266. PubMed

Rawal R.K., Singh U.S., Chavre S.N., Wang J., Sugiyama M., Hung W., Govindarajan R., Korba B., Tanaka Y., Chu C.K. 2′-Fluoro-6′-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. Bioorg. Med. Chem. Lett. 2013;23:503–506. PubMed

Ross B.S., Reddy P.G., Zhang H.R., Rachakonda S., Sofia M.J. Synthesis of diastereomerically pure nucleotide phosphoramidates. J. Org. Chem. 2011;76:8311–8319. PubMed

Schmidt A.G., Lee K., Yang P.L., Harrison S.C. Small-molecule inhibitors of dengue-virus entry. PLoS Pathog. 2012;8:e1002627. PubMed PMC

Vere Hodge R.A. Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA. Antivir. Res. 2014;111:143–153. PubMed PMC

Vere Hodge R.A. Meeting report: 28th international conference on antiviral research in Rome, Italy. Antivir. Res. 2015;123:172–187. PubMed PMC

Vere Hodge R.A. Meeting report: 29th international conference on antiviral research in La Jolla, CA, USA. Antivir. Res. 2017;137:23–40. PubMed PMC

Najít záznam

Citační ukazatele

    Možnosti archivace